Skip to main content
Sign In

Search

Search for a Specific Type of Clinical Trial
Note: This page will take a moment to download because of the quantity of trials.

Feedback

Did you have problems using this page? Please fill out our Feedback Form

Clinical Trials

Volunteer to Be Part of a Research Study

Page through all School of Medicine clinical and research trials below. There are two categories:

  • Detailed Trial Descriptions, submitted by researchers, includes trial specifics and contact information.

  • Additional Clinical Trials, which include basic study details. To contact the researcher either Google the PI (primary investigator) name or use our campus directory.

If you are a researcher seeking volunteers and your study is not posted, please
submit your Web ad here.
  

Detailed Trial Descriptions

 Results From Research and Clinical Trials : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 130.
TitleStudy GoalsEligibility CriteriaContact Information
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 5, items 1 to 30 of 130.
Cognitive Dysfunction in Parkinson's Disease 10-0771
This research study plans to use simultaneous brain scans and memory tasks to see if stimulating certain areas of the brain improves thinking and memory. This is not a treatment study
Healthy males over 50 with Parkinson's disease on stable doses of medication and have no metal in the body (dental work may be ok).
PI: Kluger, Benzi
  • 303-734-4718
  • jo.shattuck@ucdenver.edu
EFFECTS OF TESTOSTERONE THERAPY IN YOUNG ADOLESCENTS WITH KLINEFELTER SNDROME (47.XXY) 11-0874
This study will study the effects of testosterone therapy on behavior, mood, problem solving, attention span, and motor skills in adolescent males with Klinefelter syndrome in early puberty. During this period in early puberty there is a lot of variability in how and when doctors start testosterone therapy. This study will evaluate if there are benefits to starting testosterone therapy in early puberty.
Participants with Klinefelter syndrome in early puberty (around age 10-15).
PI: Tartaglia, Nicole
  • 720-777-8361
  • susan.howell@childrenscolorado.org
Join a research study that helps you lose weight and become more fit! 13-1551
Seeking volunteers for a research study testing muscle lipid metabolism and diabetes risk before and after a weight loss and exercise training intervention.
Pre-diabetic Age 30-60 BMI over 30 Male or female non-smoking
PI: Bergman, Bryan
  • (303)724-3968
  • diabetesresearch@ucdenver.edu
Managing Celiac Disease May Be More Than a Gluten-free Diet 13-0176
The CeliAction Study is a clinical research study designed to evaluate the safety and effectiveness of an investigational medication for people with celiac disease.
Diagnosed with celiac disease On a gluten-free diet for at least 11 months Have experienced at least one moderate or severe celiac symptom in the past month
PI: Freeman, Stephen
  • 303-724-7875
  • katelyn.cowan@ucdenver.edu
Are you interested in losing weight? 10-0251
Volunteers needed for a research weight loss study to examine the neuronal and behavioral changes that occur with different weight loss interventions (weight loss surgery or diet).
- Are 21-65 years old - Have no metal in your body - Maintained your current weight for the last 6 months - Weigh 350 pounds or less - Have a body mass index of 35 or higher (check it out at http://nhlbisupport.com/bmi/)
PI: Cornier, Marc
  • 303-724-9115
  • Jamie.bechtell@ucdenver.edu
Are you interested in a supervised weight loss intervention? 12-1352
Volunteers needed for a research weight loss study to examine the neuronal and behavioral changes that occur with different weight loss interventions.
- 21-65 years old - Non- smoker - Non- Diabetic - Exercise no more than 1 time a week - Maintained your current weight for the last 6 months - Have a body mass index of 30 -40 (check it out at http://nhlbisupport.com/bmi/
PI: Cornier, Marc
  • 303-724-9024
  • mailto:allison.hild@ucdenver.edu
Are you a Parkinson's patient not requiring symptomatic treatment with drugs? 13-2808
This research study explores the effects of an FDA approved drug on Parkinson's disease.
Recently diagnosed Parkinson's patients who are not taking any drugs for symptomatic relief or are willing to go off drugs for the duration of the study with neurologist approval. We are also looking for healthy control participants.
PI: Freed, Curt
  • 303-724-6015
  • Mary.wang@ucdenver.edu
The Health Influences in Puberty "HIP" study 07-0988
Research study about puberty and risk for type 2 diabetes
Healthy boy between 11 and 13 years of age Healthy girl between 9 and 11 years of age
PI: Kelsey, Megan
  • 720-777-6148
  • allison.hilkin@childrenscolorado.org
Volunteers with Alzheimer’s Disease Needed for Memory Study 12-1273
To examine the safety and efficacy of the study drug, Sargramostim (Leukine®), on memory in adults with Mild-to-Moderate Alzheimer’s Disease.
1. Age 55 to 85 years; 2. Should have a mild-to-moderate Alzheimer's Disease diagnosis (Mini-Mental State Examination 10-26 inclusive); 3. If on anti-dementia treatment should be on stable treatment for at least 2 months (i.e. cholinesterase inhibitor and/or Memantine or Axona); 4. Stable on all other medications for at least 30 days prior to screen; 5. Should be fluent in English; 6. Should be physically able to participate by medical history, clinical exam and tests; 7. Should have a study partner to accompany them to scheduled visits.
PI: Potter, Huntington
  • 303-724-2997
  • joseph.daniels@ucdenver.edu
Healthy Hispanic Female Adults Needed 07-0816
For brain imaging research study on how the brain works with we taste sweets. Your participation could help us to develop treatments and preventive measures for anorexia nervosa and obesity
Healthy females 22 to 29 who are right-handed, free of medication with no serious medical conditions, permanent metal implants or braces/retainers, and are at a healthy body weight.
PI: Frank, Guido
  • 720-777-4026
  • imaging.research@childrenscolorado.org
Do you have high blood pressure? 13-3174
Researchers at the University of Colorado Hospital are conducting a research study to help predict if blood pressure medications will work for you.
Subject must be between 30 and 75 years of age and have a diagnosis of uncontrolled hypertension (high blood pressure).  As part of the study, you may be eligible for free medication and free clinic visits to check your blood pressure
PI: Monte, Andrew
  • 303-724-7871
  • hanna.flaten@ucdenver.edu
T•A•C•I•T - Therapy After Cochlear Implants Using Telemedicine 12-1103
This research plans to learn more about the use of telemedicine as a means of providing therapy to children who have a cochlear implant(s). While Auditory-Verbal Therapy has typically been delivered in person, many people are starting to access therapy over the internet. We are conducting this research to determine if the outcomes of therapy are the same when AVT is delivered in person and via telemedicine.
The TA•C•I•T team is looking for children ages 6 mos.-6 yrs. old who were implanted with cochlear implant(s) before age  3 ½..  Each child will spend nine months in both the in-person and telemedicine condition. The therapist will remain the same throughout the study. Total participation will last 18 months. The child will be tested three times: once when the study starts, and every nine months after that. A qualified study team member will administer speech, listening, and language tests to the child. They will also receive tests to identify how well their auditory area of the brain is developing.
PI: Grigsby, Jim
  • 303.556.5804
  • tacit@ucdenver.edu
Participants with Chronic Kidney Disease Needed for a Research Study about Phosphate 13-0328
We are looking for men and women to participate in a research study examining whether lowering blood levels of phosphate will improve blood vessel function.
We need men and women who:  -are age 40-79 years old; women must be post-menopausal;  -have chronic kidney disease stage 3b or 4 (estimated GFR 15-45 ml/min);  -are not taking phosphate binders;  -do not have high blood phosphate (>5.5 mg/dL).
PI: Jovanovich, Anna
  • 303-724-7790
  • mikaela.malaczewski@ucdenver.edu
ESS-NSPAS Study 14-1808
Bayer HealthCare is sponsoring a medical research study to look at the effectiveness of Essure after having a procedure (NovaSure) that decreases your heavy menstrual bleeding. Both Essure and NovaSure are approved by the FDA. This study is enrolling patients now and you may qualify to participate.
Are you currently using the Essure method of contraception? Are your periods heavy, frequent or prolonged? One important prerequisite is - you must have had a successful Essure placement AND be willing to undergo a NovaSure endometrial ablation, a treatment option for heavy menstrual bleeding (menorrhagia).
PI: Tocce, Kristina
  • 303-724-5559
  • christina.gavito@ucdenver.edu
Type 2 Diabetes and Exercise Research Study 10-1393
To research the effects of an investigational drug on exercise capacity and blood vessel function​.​
Person 30-60 with Type 2 diabetes who exercise vigorously less than one hour per week and have normal blood pressure. Must not have smoked for at least one year and have a BMI between 25-39.9.
PI: Schauer, Irene
  • 720-848-6688
  • Katie.Rogers@ucdenver.edu
Volunteers with Chronic Kidney Disease needed for a Uric Acid Lowering Research Study 10-0625
To understand the effect of lowering serum uric acid levels on vascular function in individuals with CKD by comparing Allopurinol therapy and a placebo.
Persons 18+ with moderate chronic kidney disease (CKD stage III) with estimated glomerular filtration rates  between 30-60 mL/min/1.73m2
PI: Jalal, Diana
  • 303-724-2275
  • Emily.decker@ucdenver.edu
Research Study: "Anxiety Risk in Teens" 12-0424
To learn more about risk factors for anxiety in adolescents with cyclic vomiting syndrome.
Adolescents 13-18 who have been diagnosed with either an anxiety disorder or cyclic vomiting syndrome
PI: Tarbell, Sally
  • 720-777-6255
  • sally.tarbell@ucdenver.edu
Are you interested in learning about how your breast milk helps your baby grow? 12-0629
To find out how maternal size and diabetes status affect her breast milk To find out what unique parts of breast milk may affect how infants grow. To learn how to ensure infants receive the best nutrition possible
Women 20-35 who are at least 28 weeks into their pregnancy and planning on exclusively breastfeeding their infant for at least 4 months and delivering at University of Colorado Hospital.
PI: Krebs, Nancy
  • 303-724-3309
  • Bridget.Young@ucdenver.edu
Free Family Therapy for Youth with Mood Problems 11-1048
Helping youth and their families understand and cope with mood swings, develop plans for preventing moods from getting worse, communicate more effectively and solve family problems
  • Youth between 9-17 who has recently had significant mood swings, has at least one parent with bipolar disorder and does not abuse alcohol or substances. 
  • Must agree not to participate in family therapy with another provider for the first year.
PI: Schneck, Christopher
  • 303-492-1668
  • Anna.Frye@colorado.edu
Genital Herpes? 13-2122
This study will look at the body's immune response (how the body fights infection) to the onset of genital herpes.  1-2 study visits for blood draws over the course of 3 months.
  • 18+ years of age
  • Have developed an outbreak of genital herpes within the last 10 days.
PI: Levin, Myron
  • 303/724-2454
  • nancy.lang@ucdenver.edu
Seeking Children Ages 3 to 17 with NO History of Allergies, Eczema or Asthma HS-2581
The goal of this study is to determine why some individuals with atopic dermatitis are at increased risk for skin infections.
  • Between the ages of 3-17 
  • No history of allergies, eczema or asthma
PI: Leung, MD., Ph.D, Donald
  • 303-398-1409
  • lairsmithj@njhealth.org
Induction of Labor at 39 Weeks Pregnant versus Expectant Management 13-2085
Pregnant women are invited to participate in a research study which plans to learn more about whether coming to the hospital and having your labor started with medicine (ie., labor induction) at 39 weeks of pregnancy can improve the baby's health at birth when compared with waiting for labor to start on its own.
  • First pregnancy (no previous pregnancy beyond 20 weeks) 
  • Single baby (not twins or triplets) 
  • Planning to deliver vaginally and are at least 34 weeks pregnant 
  • Plan to deliver at University of Colorado Hospital or Denver Health Hospital
PI: Gibbs MD, Ronald
  • 303-724-2005
  • kathy.a.hale@ucdenver.edu or jocelyn.phipers@ucdenver.edu
Pregnant Participants Needed: A Phase II, Multicenter, Randomized, Observer-Blind, Controlled Study to Evaluate Safety and Immunogenicity of a Trivalent Group B Streptococcus (GBS) Vaccine in Healthy Pregnant Women 13-3019
Pregnant women are invited to participate in a research study which plans to learn about antibody (substance produced by the body to fight disease) levels in mothers and infants whose mothers have received the GBS vaccine between 24-34 6/7 weeks of their current pregnancy.  the study will also look at antibody levels in mother's breast milk.
  • Healthy pregnant woman 18-40 years of age 24 0/7 through 34 6/7 weeks pregnant 
  • Planning to breastfeed for at least 90 days after delivery 
  • Plan to deliver at University of Colorado Hospital
PI: Gibbs MD, Ronald
  • 303-724-2005
  • sarah.schwartz@ucdenver.edu
Healthy Volunteers Needed 13-3002
The Department of Neurology is looking for healthy volunteers to participate in a research study examining blinking and spasms in people with Blepharospam compared to healthy controls
  • Between the ages of 50-80
  • Must not have any metal in your body
  • In good general health
PI: Berman, Brian
  • 303-724-5865
  • erika.shelton@ucdenver.edu
Healthy Volunteers Needed for a research study of drug levels in blood and hair. 13-0427
This study plans to learn more about how tenofovir and emtricitabine (Truvada) build up in cells in blood and hair. Participation will include two 12 week dosing periods separated by a 12 week washout period (total duration is 36 weeks). Eligible participants will be given the supply of medications for the study.
  • Subject is age 18 to 50 years 
  • Subject is ambulatory 
  • Subject is able to comply with directly observed dosing procedures, including use of audio-visual streaming technology 
  • Subject is able to give informed consent 
  • Subject has a minimum scalp hair length of 2 cm in the occipital region. 
  • Subject is NOT pregnant, planning to become pregnant, or currently breastfeeding
  • Subject is low risk for HIV-1 infection 
  • Subject does NOT have any active psychiatric illness(es), social condition(s), or alcohol/drug abuse 
  • Subject does NOT have history of non-traumatic, pathologic bone fractures 
  • Subject does NOT have any medical conditions that alter red blood cell kinetics 
  • Subject does NOT have any uncontrolled medical conditions that would interfere with the study conditions
  • Subject does NOT have contraindicated concomitant medications
PI: Anderson, Peter
  • 3037248296
  • ariel.hodara@ucdenver.edu
Overweight? Women with a BMI of 30-40 needed for a birth control research study!! 13-2665
The University of Colorado School of Medicine’s Department of OB/GYN is seeking healthy volunteers for a research study of a new birth control pill.
Eligible participants must:
  • Have a BMI 32-40 
  • Be 21-35 years old
  • Have regular menstrual cycles
PI: Teal, Stephanie
  • 303 724 5284
  • cricket.mchugh@ucdenver.edu
Research Participants Needed 14-0770
We are looking for healthy participants to serve as a standard for comparison when describing physical function outcomes before and during prosthetic rehabilitation.
Inclusion Criteria:
  1. 50-85 years of age. 
  2. Able to walk continuously without assistance (i.e., do not use a cane or walker) for 10 minutes and physically active (e.g., participate in recreational activities like walking, jogging, hiking). 
  3. No neurological, vascular or cardiac problems that limit function.
  4. Body mass inde.
PI: Christiansen, Cory
  • 303-724-9590
  • krista.m.sanchez@ucdenver.edu
Shingles Vaccine Clinical Research Trial 13-3192
This study will compare responses to two shingles vaccines - the current FDA approved shingles vaccine and an investigational shingles vaccine
  • 70-85 years of age
  • In general good health 
  • No prior history of shingles 
  • Have never received the shingles vaccine
PI: Levin, MD, Myron
  • 303/724-2454
  • nancy.lang@ucdenver.edu
Thinking About Starting a New Physical Activity Program? 14-0275
This study will examine psychosocial predictors of physical activity. Participants will become members of the Anschutz Health and Wellness Center and will complete a variety of questionnaires and two fitness assessments over 12 weeks. Most of the questionnaires are completed online.
  • 30-89 years of age
  • Able to read and understand English
  • Not participating in regular physical activity for the past 3 months
  • Joining the Anschutz Health and Wellness Center
  • No physical contraindications to physical activity
  • No existing diagnoses of cardiovascular disease
  • Not pregnant.
PI: Hooker, Stephanie
  • 303-724-8228
  • stephanie.hooker@ucdenver.edu
The Role of Gut Bacteria in the Development of Type 1 Diabetes 11-1144
The goal of the research is to better understand the role bacteria that live in the intestine in the development of type 1 diabetes
  • Patients diagnosed with type 1 diabetes in the last 6 months 
  • Subjects with islet autoantibodies 
  • Subjects who do not have islet antibodies and are first-degree relatives of patients with diabetes or subjects with islet antibodies
  • 1-45 years of age
PI: Zipris, Danny
  • 303-724-6820 or 303-724-6821
  • aimon.alkanani@ucdenver.edu or james.needell@ucdenver.edu

​Additional Clinical Trails

 Results From Research : Selected site
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 18, items 1 to 30 of 511.
Protocol TitlePI NameInstitution Number
Data pager
<
>
Page Size
PageSizeComboBox
select
 |  Displaying page 1 of 18, items 1 to 30 of 511.
A Randomized Comparison of NeoCart to Microfracture for the Repair of Articular Cartilage Injuries in the Knee. Sponsor Protocol No. 8-01. WIRB Protocol No.20100579
McCarty, Eric12-0796
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study Evaluating Two Doses of Subcutaneous Pulsatile GnRH Administered via OmniPod Pump for Ovulation Induction in Female Subjects with Primary Amenorrhea with Hypogonadotropic Hypogonadism. Sponsor Protocol No. 000070. WIRB Protocol No. 20140452
Santoro, Nanette13-2352
A Phase 1b, multi-center, two parallel group, open-label, drug-drug interaction study to assess the effect of LDE225 on the pharmacokinetics of bupropion and warfarin in patients with advanced solid tumors. Sponsor Protocol No. CLDE225A2112. WIRB Protocol No.20130681
Lewis, Karl13-2556
A Randomized Phase 2 Study of Oral AP26113 in Patients with ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Been Treated with Crizotinib. Sponsor Protocol No. AP26113-13-201. WIRB Protocol No.20131562
Camidge, David13-2648
A MULTI-CENTER,OPEN LABEL, FIRST IN HUMAN, PHASE I DOSE ESCALATION STUDY TO INVESTIGATE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO6839921, AN MDM2 ANTAGONIST FOLLOWING INTRAVENOUS ADMINISTRATION IN PATIENTS WITH ADVANCED MALIGNANCIES, INCLUDING ACUTE MYELOID LEUKEMIA (AML). Sponsor Protocol No. NP28903. WIRB Protocol No. 20140542
Gore, Lia13-2649
A 12-Week Multicenter, Randomized, Double-Blind,Placebo-Controlled Study Comparing the Efficacy and Safety of LY2439821 to Etanercept and Placebo in Patients with Moderate to Severe Plaque Psoriasis with a Long-Term Extension Period. Sponsor Protocol No. I1F-MC-RHBC(b). WIRB Protocol No. 20121432
Armstrong, April13-2723
A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcinerurin inhibitor vs mycophenolate with standard calcineurin inhibitor in de novo renal transplantation- Advancing renal TRANSplant eFficacy and safety Outcomes with an eveRolimus-based regiMen (TRANSFORM). Sponsor Protocol No. CRAD001A2433. WIRB Protocol No. 20140590
Wiseman, Alexander13-2918
A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Response Following Platinum based Chemotherapy. Sponsor Protocol No. D0816C00002. WIRB Protocol No. 20131789
Davidson, Susan13-2969
BRF117277: A Phase II, Open-Label, Multicentre Study of Dabrafenib plus Trametinib in Subjects with BRAF Mutation-Positive Melanoma that has Metastasized to the Brain. WIRB Protocol No. 20140064
Lewis, Karl13-3079
Evaluation of Acute Rejection Rates in de novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (belatacept) -based Immunosuppression. Sponsor Protocol No, IM103177. WIRB Protocol No. 20132295
Wiseman, Alexander13-3123
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF THE SAFETY AND EFFICACY OF 3-MONTH SUBCUTANEOUS REGN1033 TREATMENT IN PATIENTS WITH SARCOPENIA. Sponsor Protocol No. R1033-SRC-1239. WIRB Protocol No.20131518
Schwartz, Robert13-3265
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Solid Tumors, Including Glioma, with an IDH1 Mutation Sponsor Protocol No. AG120-C-002 WIRB Protocol No. 20140544
Gore, Lia14-0012
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects with Advanced Hematologic Malignancies with an IDH1 Mutation. Sponsor Protocol No. AG120-C-001. WIRB Protocol No. 20140421
Pollyea, Daniel14-0013
A Phase Ib dose escalation/randomized phase II multicenter, open-label study of BYL719 in combination with cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma. Sponsor Protocol No. CBYL719X2104. WIRB Protocol No.20140692
Jimeno, Antonio14-0034
A safety study for MSB0010445 in combination with Stereotactic Body Radiation in advanced melanoma subjects following prior treatment with ipilimumab Sponsor Protocol No. EMR 062235-005 WIRB Protocol No. 20140683
Lewis, Karl14-0050
Phase 1 study of ONT-10, a liposomal MUC1 cancer vaccine, in patients with solid tumors. Sponsor Protocol No. ONT-10-001. WIRB Protocol No. 20140202
Borges, Virginia14-0063
Maintenance therapy with ONT-10, a liposomal MUC1 cancer vaccine, in patients who have previously received ONT-10. Sponsor Protocol No. ONT-10-002. WIRB Protocol No. 20140221
Borges, Virginia14-0064
A Phase 1b Dose Escalation Study of Vantictumab (OMP-18R5) in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer. Sponsor Protocol No. 18R5-002. WIRB Protocol No. 20140743
Diamond, Jennifer14-0065
International, multicenter, open-label, treatment-extension study for subjects who completed a Phase 1 or Phase 2 parental study to continue receiving treatment with SAR245408 or SAR245409 as a monotherapy or as a combination regimen. Sponsor Protocol No. TED12414. WIRB Protocol No. 20120931
Gore, Lia14-0079
A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd- Sulfate) in Combination with Docetaxel, Compared with Placebo in Combination with Docetaxel, in Patients receiving second line treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB – IV)(SELECT-2) Sponsor Protocol No. D1532C0064 WIRB Protocol No. 20121812
Oton, Ana14-0084
A multicenter, randomized, double-blind, placebo-controlled phase III trial of tecemotide versus placebo in subjects with completed concurrent chemo-radiotherapy for unresectable stage III non-small cell lung cancer (NSCLC). Sponsor Protocol No. EMR-63325-021. WIRB Protocol No. 20140155
Oton, Ana14-0085
A RANDOMIZED, DOUBLE-BLIND TRIAL ASSESSING THE IMPACT OF METHOTREXATE DISCONTINUATION ON THE EFFICACY OF SUBCUTANEOUS TOCILIZUMAB WITH METHOTREXATE THERAPY. Sponsor Protocol No. ML28776. WIRB Protocol No. 20132070
Striebich, Christopher14-0087
Evaluation of Potential Allergenicity of New Soybean Varieties Sponsor Protocol No. Monsanto Soy Allergen WIRB Protocol No.20131161
Fleischer, David14-0097
A single arm, open-label, phase II study to assess the efficacy of the dual VEGFR-FGFR tyrosine kinase inhibitor, lucitanib, given orally as a single agent to patients with FGFR1-driven lung cancer. Sponsor Protocol No. E-3810-II-02. WIRB Protocol No. 20140760
Camidge, David14-0100
A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244, Hyd-Sulfate) in Combination with Dacarbazine Compared with Placebo in Combination with Dacarbazine as First Systemic Therapy in Patients with Metastatic Uveal Melanoma (SUMIT) Sponsor Protocol No. D1344C00001 WIRB Protocol No.20141762
Lewis, Karl14-0108
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects with Advanced Solid Tumors. Sponsor Protocol No. PT-112-101. WIRB Protocol No. 20140867
Camidge, David14-0151
An Open-Label, Randomized, Phase 3 Trial of Nivolumab versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer Sponsor Protocol No. CA209026 WIRB Protocol No. 20140357
Camidge, David14-0243
A MULTICENTER PHASE 1A/1B ASCENDING DOSE STUDY OF DCC-2701 TO ASSESS SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS IN PATIENTS WITH ADVANCED SOLID TUMORS Sponsor Protocol No. DCC-2701-01-001 WIRB Protocol No. 20142004
Leong, Stephen14-0244
A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors. Sponsor Protocol No. M14-237. WIRB Protocol No.20140725
Weekes, Colin14-0251
Open-label, single-arm extension study to the double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis. Sponsor Protocol No. CFTY720D2306E1. WIRB Protocol No. 20140779
Corboy, John14-0289


Contact Us

Building 500 - 13001 E. 17th Place, Campus Box C290, Aurora, CO 80045

Learn more